Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception
Increased 2025 financial guidance
Knight Therapeutics Reports Third Quarter 2025 Results
Seeking Alpha / 20 hours ago 2 Views
Seeking Alpha / 20 hours ago 2 Views
Achieved record-high quarterly revenues, Adjusted EBITDA1 and Adjusted EBITDA per share1 since inception
Increased 2025 financial guidance
Comments